白蛋白结合型紫杉醇作为三线及以上方案治疗晚期恶性肿瘤的临床观察

摘要

目的：观察含白蛋白结合型紫杉醇作为三线及以上方案治疗晚期恶性肿瘤的临床疗效及安全性。方法10例晚期恶性肿瘤患者为此次观察对象，全部接受含白蛋白结合型紫杉醇（260 m －2第1天）或（130 m －2第1天，第8天）方案化疗，均为三线及以上化疗，21 d 为一周期，共2～6个周期，分别根据 RECIS1．1及 NCI4．0标准评价。结果10例患者中，有1例部分缓解，5例稳定，4例进展，客观有效率（RR）为10％，疾病控制率（DCR）为60％，不良反应中1例患者出现与白蛋白结合型紫杉醇相关的Ⅳ度骨髓抑制，其他患者均未发生严重不良反应。结论白蛋白结合型紫杉醇治疗晚期恶性肿瘤效果较好，耐受性良好，不失为部分晚期难治性恶性肿瘤患者的一种选择。%Objective To observe the efficacy and safety of albumin-bound paclitaxel as third-line and beyond therapy in the treatment of patients with advanced malignant tumors.Methods This study included 10 patients who underwent third-line and beyond chemo-therapy with albumin-bound paclitaxel(260 m -2 D1 or 130 m -2 D1,8)every 3 weeks.All patients with advanced malignant tumors re-ceived 2 ~6 cycles of chemotherapy.The treatment results were assessed according to RECIST1.1 and NCI4.0 criteria.Results Of the 10 patients,1 achieved partial remission(PR),5 stable disease(SD),4 progressive disease(PD).The objective response rate (RR) was 10%,and the disease control rate (DCR)was 60%.Adverse reactions occurred in 1 patient with IV degree of leukopenia related to albumin bound paclitaxel .Other patients had no serious adverse reactions.Conclusions The albumin-bound paclitaxel is effective and well tolerated in the treatment of advanced malignant tumors.So it is a choice for the treatment of some advanced refractory malignant tumors.